Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria.

Albuminuria Apolipoprotein C-III Cardiovascular Diseases Diabetes Mellitus, Type 1 / complications Diabetic Nephropathies Finland Humans
apolipoprotein C-III cardiovascular disease diabetes mellitus diabetic nephropathy dyslipidemia mortality type 1

Journal

Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 25 11 2021
medline: 29 3 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

We studied apolipoprotein C-III (apoC-III) in relation to diabetic kidney disease (DKD), cardiovascular outcomes, and mortality in type 1 diabetes. The cohort comprised 3966 participants from the prospective observational Finnish Diabetic Nephropathy Study. Progression of DKD was determined from medical records. A major adverse cardiac event (MACE) was defined as acute myocardial infarction, coronary revascularization, stroke, or cardiovascular mortality through 2017. Cardiovascular and mortality data were retrieved from national registries. ApoC-III predicted DKD progression independent of sex, diabetes duration, blood pressure, HbA The impact of apoC-III on MACE risk and mortality is restricted to those with albuminuria among individuals with type 1 diabetes. This study also revealed that apoC-III predicts DKD progression, independent of the initial DKD category.

Identifiants

DOI: 10.1111/joim.13412 PMID: 34817888 PMC: PMC9298713
pubmed: 34817888
doi: 10.1111/joim.13412
pmc: PMC9298713
doi:

Substances chimiques

Apolipoprotein C-III 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-349

Informations de copyright

© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.

Références

J Clin Invest. 1995 Dec;96(6):2601-5
pubmed: 8675624
Diabet Med. 2001 Jan;18(1):59-67
pubmed: 11168343
J Am Coll Cardiol. 2017 Feb 21;69(7):789-800
pubmed: 28209220
Circ Res. 2016 Feb 19;118(4):547-63
pubmed: 26892957
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1338-49
pubmed: 27150391
Nat Immunol. 2020 Jan;21(1):30-41
pubmed: 31819254
South Med J. 1988 Apr;81(4):469-73
pubmed: 3128878
Diabetologia. 2009 Dec;52(12):2522-30
pubmed: 19816673
Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):513-9
pubmed: 21183731
Nat Med. 2019 May;25(5):805-813
pubmed: 31011203
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Metabolism. 1994 Mar;43(3):333-47
pubmed: 8139482
BMJ. 2011 Sep 08;343:d5364
pubmed: 21903695
Cardiovasc Res. 1997 Apr;34(1):55-68
pubmed: 9217873
Diabetes Care. 2011 May;34 Suppl 2:S285-90
pubmed: 21525470
Circulation. 2000 Oct 17;102(16):1886-92
pubmed: 11034934
J Am Soc Nephrol. 2012 Mar;23(3):516-24
pubmed: 22266664
Circulation. 2006 Aug 15;114(7):681-7
pubmed: 16894036
Diabetes Care. 2016 Aug;39(8):1408-15
pubmed: 27271183
J Clin Lipidol. 2021 Jan-Feb;15(1):235-242
pubmed: 33257283
N Engl J Med. 2015 Jul 30;373(5):438-47
pubmed: 26222559
Ren Fail. 2006;28(6):483-6
pubmed: 16928617
N Engl J Med. 2014 Dec 4;371(23):2200-6
pubmed: 25470695
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212
pubmed: 28473441
J Diabetes Complications. 2005 Jan-Feb;19(1):18-25
pubmed: 15642486
Diabetes Care. 2014 Aug;37(8):2374-82
pubmed: 24879842
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Lipid Res. 2019 Aug;60(8):1432-1439
pubmed: 31203233
N Engl J Med. 2014 Jul 3;371(1):22-31
pubmed: 24941081
J Am Coll Cardiol. 2013 Jan 29;61(4):427-436
pubmed: 23265341
Front Endocrinol (Lausanne). 2020 Jul 28;11:474
pubmed: 32849270
Diabetes Care. 1996 Jul;19(7):689-97
pubmed: 8799621
Diabetes. 2009 Jul;58(7):1651-8
pubmed: 19401416
Drugs. 2019 Aug;79(12):1349-1354
pubmed: 31301033
N Engl J Med. 2014 Jul 3;371(1):32-41
pubmed: 24941082
Clin Chem. 2008 Aug;54(8):1325-30
pubmed: 18556334
JAMA Cardiol. 2020 May 1;5(5):540-548
pubmed: 32101259
Diabetes Care. 2013 Aug;36(8):2317-23
pubmed: 23514730
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10090-4
pubmed: 15210953
Diabetes Care. 2005 Aug;28(8):2019-24
pubmed: 16043748
J Clin Invest. 2019 Jul 11;129(10):4165-4179
pubmed: 31295146
J Intern Med. 2022 Mar;291(3):338-349
pubmed: 34817888

Auteurs

Fanny Jansson Sigfrids (F)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-1192-348X

Lars Stechemesser (L)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
First Department of Medicine, Paracelsus Medical University, Salzburg, Austria.

Emma H Dahlström (EH)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0003-1271-8696

Carol M Forsblom (CM)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-3354-7454

Valma Harjutsalo (V)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
ORCID: 0000-0003-3568-9779

Raimund Weitgasser (R)

First Department of Medicine, Paracelsus Medical University, Salzburg, Austria.
Department of Medicine, Diabetology, Wehrle-Diakonissen Hospital, Salzburg, Austria.

Marja-Riitta Taskinen (MR)

Heart and Lung Centre, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-6229-3588

Per-Henrik Groop (PH)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
ORCID: 0000-0003-4055-6954
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations urologiques › Protéinurie › Albuminurie › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Apolipoprotéines › Apolipoprotéines C › Apolipoprotéine C-III › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Maladies cardiovasculaires › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Diabète de type 1 › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Complications du diabète › Néphropathies diabétiques › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Régions géographiques › Europe › Pays nordiques et scandinaves › Finlande › Apolipoprotein C-III predicts cardiovascular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Apolipoprotein C-III predicts cardiovascular...